Eleven Abstracts Selected for Presentation,
Including Four Highlighting Pharmacokinetic and Global Surveillance
Data for Eravacycline
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical
stage biopharmaceutical company developing novel antibiotics to
treat life-threatening multidrug-resistant (MDR) infections, today
announced upcoming data presentations at the American Society for
Microbiology (ASM) Microbe 2017 Annual Meeting, taking place June
1-5, 2017 in New Orleans, LA. In total, eleven presentations
will be given including pharmacokinetic and global surveillance
data for the Company's phase 3 antibiotic drug candidate,
eravacycline, one oral presentation highlighting TP-6076 phase 1
single-ascending dose (SAD) study results, one poster presentation
featuring TP-271 SAD study results, and additional pipeline program
data.
“We continue to be pleased with the additional supportive data
generated for eravacycline which shows consistent potency against
drug-resistant bacteria in ongoing global surveillance studies,”
said Guy Macdonald, President and Chief Executive Officer of
Tetraphase. “We also have been highly encouraged by the preclinical
profiles observed to date with both TP-271 and TP-6076, and we look
forward to sharing the data from our first-in-human, phase 1 SAD
studies for each of these promising candidates with the medical
community at ASM Microbe this year.”
Details for the data presentations at ASM Microbe 2017 are as
follows:
Eravacycline Data Presentations
Poster #54: Activity of Eravacycline Against
Carbapenem Resistant Enterobacteriaceae and Acinetobacter
baumanniiDate and time: Saturday, June 3 from
12:15 – 2:15 p.m. CTSession info: Session 185 -
AAID01 - Antibacterial Resistance: In vitro Activity and Resistance
to Tigecycline, Fosfomycin and Derivatives
Poster #189: Pharmacokinetics-Pharmacodynamics
(PK-PD) of Efficacy for Eravacycline Against Escherichia coli in an
In Vitro Infection ModelDate and time: Sunday,
June 4 from 12:15 – 2:15 p.m. CTSession info:
Session 341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New
Antimicrobial Agents
Poster #190: Compartmental Pharmacokinetics of
Eravacycline following Intravenous Administration in
RabbitsDate and time: Sunday, June 4 from 12:15 –
2:15 p.m. CTSession info: Session 341 - AAID03 -
Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial
Agents
Poster #191: PK/PD of the Novel Fluorocycline
Eravacycline is Efficacious in a Murine E. coli Thigh
Model.Date and time: Sunday, June 4 from 12:15 –
2:15 p.m. CTSession info: Session 341 - AAID03 -
Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial
Agents
Clinical Pipeline Data Presentations
Oral Presentation #8: Safety,
Tolerability and Pharmacokinetics of Single Doses of TP-6076, a
Novel Fully Synthetic Tetracycline, in a Phase 1 StudyDate
and time: Saturday, June 3 at 4:30 p.m. CTSession
info: Session 264 - Development of New Drugs and
Strategies for Hospital-acquired Pneumonia Caused by MDR Pathogens,
Room 215
Poster #198: Safety, Tolerability and
Pharmacokinetics of Single Intravenous Doses of TP-271, a Novel
Fluorocycline AntibioticDate and time: Sunday,
June 4 from 12:15 – 2:15 p.m. CTSession info:
Session 341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New
Antimicrobial Agents
Preclinical Pipeline Data Presentations
Poster #36: The Novel Fluorocycline TP-271 is
Efficacious in a Nonhuman Primate Model of Inhalation
Anthrax.Date and time: Friday, June 2 from 12:45 –
2:45 p.m. CTSession info: Session 035 - AAID -
Respiratory Tract Infections: Clinical and Laboratory Studies
Poster #94: The Novel Fluorocycline TP-271 is
Efficacious in a Murine A. baumannii Pneumonia Model.Date
and time: Friday, June 2 from 12:45 – 2:45 p.m.
CTSession info: Session 037 - AAID01 -
Antibacterial Resistance: Laboratory Studies of Antimicrobial
Resistance
Poster #332: TP-6076, A Fully Synthetic
Tetracycline Antibacterial Agent, Is Highly Potent against a Broad
Range of Pathogens, including Carbapenem-resistant
EnterobacteriaceaeDate and time: Sunday, June 4
from 12:15 – 2:15 p.m. CTSession info: Session 351
- AAID11 - New Antimicrobial Agents: New Antibacterial Agents
II
Multidrug-Resistant Infection Prevalence Data
Presentations
Poster #95: Prevalence of
Multidrug-Resistant Acinetobacter baumannii (MDR AB) by ICU Status
and Setting in USA Hospitals in 2015-2016: A Multicenter
StudyDate and time: Saturday, June 3 from 12:15 –
2:15 p.m. CTSession info: Session 187 - AAID01 -
Antibacterial Resistance: Molecular Epidemiology of
Non-fermentative Gram-negative bacilli
Poster #100: Prevalence of
Multidrug-Resistance (MDR) in Enterobacteriaceae (ENT) by ICU
Status and Setting in USA Hospitals in 2015-2016: A Multicenter
StudyDate and time: Sunday, June 4 from 12:15 –
2:15 p.m. CTSession info: Session 338 - AAID01 -
Antibacterial Resistance: Global Surveillance of Multi-Drug
Resistant Bacteria
ASM Microbe 2017 is the integration of two of the American
Society of Microbiology’s meetings: the General Meeting and
ICAAC (Interscience Conference on Antimicrobial Agents and
Chemotherapy). Full abstracts can be found on the ASM Microbe
website at http://www.asmmicrobe.org/.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a clinical-stage biopharmaceutical
company using its proprietary chemistry technology to create novel
antibiotics for serious and life-threatening bacterial infections,
including those caused by many of the multidrug-resistant (MDR)
bacteria highlighted as urgent public health threats by the CDC.
Tetraphase has created more than 3,000 novel tetracycline analogs
using its proprietary technology platform. Tetraphase's pipeline
includes three antibiotic clinical candidates: eravacycline, which
is in phase 3 clinical trials, and TP-271 and TP-6076, which are in
phase 1 clinical trials. Please visit www.tphase.com for more
company information.
Investor Contacts:
Tetraphase Pharmaceuticals
Teri Dahlman
617-600-7040
tdahlman@tphase.com
Argot Partners
Maeve Conneighton
206.899.4940
maeve@argotpartners.com
Media Contact:
Sam Brown Inc.
Mike Beyer
312-961-2502
Mikebeyer@sambrown.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024